v3.26.1
Consolidated Statements of Cash Flows - CHF (SFr)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Consolidated Statements of Cash Flows      
Net profit / (loss) for the period SFr (6,728,246) SFr 7,055,787 SFr (10,556,227) [1]
Adjustments for:      
Net gain on Neurosterix Transaction (114,342) (13,943,595)  
Fair value of services received at zero cost recorded as income (141,018)    
Fair value of services received at zero cost recorded as other operating costs 141,018    
Value of share-based services 70,820 502,964 1,794,467
Post-employment benefits (7,218) (95,219) (62,643)
Share of the net loss of associates 4,012,443 2,177,157  
Depreciation 8,472 260,120 305,952
Net gain related to lease modification   (2,770) (318)
Finance cost / (income) net 37,607 (99,628) 312,602
Decrease / (increase) in other financial assets 1,366 (5,648) 2,317
Decrease / (increase) in trade and other receivables (4,574) 93,107 306,514
Decrease in contract asset   40,907 140,534
Decrease / (increase) in prepayments 153,354 (164,284) 53,386
Decrease / (increase) in other current assets 7,967 (7,967)  
Increase / (decrease) in payables and accruals 391,234 (1,146,084) (613,205)
Decrease in deferred income   (38,401) 324,210
Net cash used in operating activities (2,171,117) (5,373,554) (7,992,411)
Cash flows from / (used in) investing activities      
Consideration from Neurosterix Transaction 114,342 5,119,754  
Legal fees paid for Neurosterix Transaction   (473,270)  
Investment in Stalicla SA - preferred shares (285,962)    
Investment in Stalicla SA - derivative financial instruments (509,067)    
Purchase of property, plant and equipment 0 (1,273) (6,842)
Net cash from/(used in) investing activities (680,687) 4,645,211 (6,842)
Cash flows from financing activities      
Sale of treasury shares 1,228,733 240,899 2,350,512
Cost paid on sale of treasury shares (28,850) (25,782) (48,051)
Cost of treasury share issuance (6,292)   (53,600)
Proceeds from the exercise of pre-funded warrants     3,418,240
Costs paid on exercise of pre-funded warrants   (36,457) (163,069)
Principal element of lease payment (7,306) (73,688) (281,793)
Interest received   9,165 63,964
Interest paid (2,421) (9,219) (21,607)
Net cash from financing activities 1,183,864 104,918 5,264,596
Decrease in cash and cash equivalents (1,667,940) (623,425) (2,734,657)
Cash and cash equivalents at beginning of the year 3,341,738 3,865,481 6,957,086
Exchange difference on cash and cash equivalents (35,186) 99,682 (356,948)
Cash and cash equivalents at end of the year SFr 1,638,612 SFr 3,341,738 SFr 3,865,481
[1] The comparative information has been re-presented due to discontinued operations that have been reclassed to the financial line called “Net profit or loss from discontinued operations” (note 23). In the other sections of these consolidated financial statements an asterisk will indicate where comparative information has been re-presented